Brodalumab for moderate-severe hidradenitis suppurativa : An open-label multicentric cohort study in real clinical practice
© 2024 Australasian College of Dermatologists..
INTRODUCTION: The use of biological therapy is becoming increasingly common in patients with hidradenitis suppurativa (HS). Levels of serum TNF-alfa and IL17 support the role of an immune system dysregulation in the pathogenesis of HS. Brodalumab targets the receptor A of IL-17, thus having a promising role in the treatment of HS.
MATERIAL AND METHODS: A multicenter retrospective observational open-label study was conducted in two tertiary hospitals. Adults with moderate to severe HS under treatment with brodalumab 210 mg at week 0, 1, 2 and then every 2 weeks were included and assessed at weeks 0 and 16 which was the median follow-up time. Demographic and disease-related variables as well as response parameters (HiSCR and IHS4) and safety data were recorded and analysed.
RESULTS: A total of 16 patients (75% males) were included in our study. 50% of patients presented an inflammatory phenotype and mean BMI was 28.37. HiSCR was achieved in 50% of patients and mean IHS4 decreased from 24.13 to 16.81 (p = 0.002). No differences were found between those who achieved HiSCR and those who did not. Grade 2 adverse events were reported in three patients with no fatal outcomes and treatment discontinuation was advised in four patients.
CONCLUSIONS: Brodalumab seems to be effective and safe in patients with moderate to severe HS, even in those that did not respond to adalimumab, which, at the moment, is the only widely approved biologic for this indication. Thus, it stands as an interesting option for the treatment of HS.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
The Australasian journal of dermatology - (2024) vom: 10. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Osorio-Gómez, Guiovana Fernanda [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biological therapy |
|---|
| Anmerkungen: |
Date Revised 10.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1111/ajd.14267 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370864328 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370864328 | ||
| 003 | DE-627 | ||
| 005 | 20240410233547.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240410s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/ajd.14267 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1371.xml |
| 035 | |a (DE-627)NLM370864328 | ||
| 035 | |a (NLM)38597096 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Osorio-Gómez, Guiovana Fernanda |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Brodalumab for moderate-severe hidradenitis suppurativa |b An open-label multicentric cohort study in real clinical practice |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 10.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024 Australasian College of Dermatologists. | ||
| 520 | |a INTRODUCTION: The use of biological therapy is becoming increasingly common in patients with hidradenitis suppurativa (HS). Levels of serum TNF-alfa and IL17 support the role of an immune system dysregulation in the pathogenesis of HS. Brodalumab targets the receptor A of IL-17, thus having a promising role in the treatment of HS | ||
| 520 | |a MATERIAL AND METHODS: A multicenter retrospective observational open-label study was conducted in two tertiary hospitals. Adults with moderate to severe HS under treatment with brodalumab 210 mg at week 0, 1, 2 and then every 2 weeks were included and assessed at weeks 0 and 16 which was the median follow-up time. Demographic and disease-related variables as well as response parameters (HiSCR and IHS4) and safety data were recorded and analysed | ||
| 520 | |a RESULTS: A total of 16 patients (75% males) were included in our study. 50% of patients presented an inflammatory phenotype and mean BMI was 28.37. HiSCR was achieved in 50% of patients and mean IHS4 decreased from 24.13 to 16.81 (p = 0.002). No differences were found between those who achieved HiSCR and those who did not. Grade 2 adverse events were reported in three patients with no fatal outcomes and treatment discontinuation was advised in four patients | ||
| 520 | |a CONCLUSIONS: Brodalumab seems to be effective and safe in patients with moderate to severe HS, even in those that did not respond to adalimumab, which, at the moment, is the only widely approved biologic for this indication. Thus, it stands as an interesting option for the treatment of HS | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a biological therapy | |
| 650 | 4 | |a brodalumab | |
| 650 | 4 | |a hidradenitis suppurativa | |
| 700 | 1 | |a Ortiz-Álvarez, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Diaz-Ceca, Delia |e verfasserin |4 aut | |
| 700 | 1 | |a Guijarro-Sánchez, Cesar |e verfasserin |4 aut | |
| 700 | 1 | |a Conejo-Mir Sánchez, Julián |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández Crehuet, Pablo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Australasian journal of dermatology |d 1967 |g (2024) vom: 10. Apr. |w (DE-627)NLM000027162 |x 1440-0960 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:10 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/ajd.14267 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 10 |c 04 | ||